ReviewInternational journal of molecular sciences2019
A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- Liquid biopsy-based epigenetic signatures for early detection of prostate cancer: a systematic review.Frontiers in oncology · 2026Pooled it
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide.Journal of clinical medicine · 2026Article
- A four-miRNA serum panel as a diagnostic biomarker for prostate cancer: an exploratory and validation study.Frontiers in oncology · 2026Article
- Review
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
- The role of RGS12 in tissue repair and human diseases.Genes & diseases · 2025Review
- Increased GPR35 expression is correlated with poor prognosis in prostate cancer.World journal of surgical oncology · 2025Article
- Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.Discover oncology · 2025Review
- A shifting market environment and strategies fueling innovation in prostate cancer treatment.Nature biotechnology · 2025Article
- An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.Cancer cell international · 2025Article
- Sideroflexin family genes were dysregulated and associated with tumor progression in prostate cancers.Human genomics · 2025Article
- A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients.Cancer medicine · 2025Article
- Identifying MTHFD1 and LGALS4 as Potential Therapeutic Targets in Prostate Cancer Through Multi-Omics Mendelian Randomization Analysis.Biomedicines · 2025Article
- Characterisation of Castration-Resistant Cell-Derived Exosomes and Their Effect on the Metastatic Phenotype.Cancers · 2025Article
- Role of exosomes in castration-resistant prostate cancer.Frontiers in oncology · 2025Review
- Prostate cancer diagnostics: the independent and combined roles of SelectMDx and mpMRI.Central European journal of urology · 2025Article
- Cellular Synthesis of Targeted Ultrasound Molecular Imaging Probe and Its Application in Prostate Cancer Diagnosis.International journal of nanomedicine · 2025Article
- Prognostic Impact of H19/Cell Adhesion Molecules Circuitry on Prostate Cancer Biopsy.Biomedicines · 2024Article
- Prostate cancer biomarkers: from early diagnosis to precision treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of cancer-related death. Early detection of prostate cancer is largely determined by a widely used prostate specific antigen (PSA) blood test and biopsy is performed for definitive diagnosis. Prostate cancer is asymptomatic in the early stage of the disease, comprises of diverse clinico-pathologic and progression features, and is characterized by a large subset of the indolent cancer type. Therefore, it is critical to develop an individualized approach for early detection, disease stratification (indolent vs. aggressive), and prediction of treatment response for prostate cancer. There has been remarkable progress in prostate cancer biomarker discovery, largely through advancements in genomic technologies. A rich array of prostate cancer diagnostic and prognostic tests has emerged for serum (4K, phi), urine (Progensa,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.